ADMA Biologics, Inc. (NASDAQ:ADMA) Given Average Recommendation of “Buy” by Brokerages

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) have been assigned an average rating of “Buy” from the four research firms that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $7.88.

A number of analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $7.50 price objective (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. Mizuho increased their price objective on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Cantor Fitzgerald lifted their target price on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 407,000 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total value of $2,527,470.00. Following the transaction, the director now directly owns 3,208,671 shares of the company’s stock, valued at approximately $19,925,846.91. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 639,895 shares of company stock valued at $3,927,169 over the last quarter. 6.00% of the stock is owned by company insiders.

Institutional Trading of ADMA Biologics

Hedge funds have recently added to or reduced their stakes in the stock. Stephens Consulting LLC bought a new stake in ADMA Biologics during the 3rd quarter worth $36,000. Cambridge Investment Research Advisors Inc. grew its holdings in shares of ADMA Biologics by 31.3% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 3,572 shares during the last quarter. Sawgrass Asset Management LLC acquired a new position in shares of ADMA Biologics in the third quarter valued at approximately $55,000. DekaBank Deutsche Girozentrale bought a new position in ADMA Biologics in the 3rd quarter valued at approximately $58,000. Finally, Commonwealth Equity Services LLC boosted its position in ADMA Biologics by 61.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,360 shares of the biotechnology company’s stock worth $59,000 after buying an additional 6,250 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Trading Up 1.0 %

ADMA opened at $6.81 on Wednesday. The firm’s fifty day simple moving average is $6.21 and its 200 day simple moving average is $5.01. The stock has a market capitalization of $1.55 billion, a P/E ratio of -52.38 and a beta of 0.43. The company has a current ratio of 5.16, a quick ratio of 1.69 and a debt-to-equity ratio of 1.04. ADMA Biologics has a 12 month low of $3.06 and a 12 month high of $6.81.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The company had revenue of $73.90 million for the quarter, compared to analyst estimates of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. As a group, research analysts anticipate that ADMA Biologics will post 0.3 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.